Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results

Oxford, UK – Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces that it has raised $168 million in a Series B financing. This includes $43 million in convertible loan notes previously issued by Vaccitech that converted into Series B shares.

Read full release here